NCT01910389终止3 期
Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure
Carelon Research63 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2013年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 23
- 试验地点
- 63
- 主要终点
- Composite Outcome of Cardiovascular (CV) Mortality or Heart Failure (HF) Hospitalization
研究概览
简要总结
This study is a multi-center, prospective, randomized, double blind, placebo-controlled clinical trial. Subjects in the study will be adults with New York Heart Association (NYHA) Class II-IV heart failure (HF) due to left ventricular systolic dysfunction (LVSD), left ventricular ejection fraction (LVEF) <0.40, and secondary pulmonary hypertension (PH). The purpose of the study is to evaluate the safety, effectiveness, and effects of tadalafil compared to placebo on the subjects' functional capacity / quality of life.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female age 21 years or older.
- •NYHA Class II-IV HF with LVSD (most recent LVEF < 0.40).
- •At high risk of future clinical instability, indicated by EITHER:
- •a hospitalization for the primary reason of decompensated HF within the 12 months prior to screening; OR a plasma B-type Natriuretic Peptide (BNP) level ≥ 300 pg/ml or N-terminal prohormone of brain natriuretic peptide (NT-proBNP) ≥1800pg/ml measured during a period of clinical stability in the 3 months prior to screening.
- •Documented secondary PH within the last 6 months
- •Medication and device treatment according to current American Heart Association/American College of Cardiology (AHA/ACC) guidelines.
- •Stable medical therapy for 30 days prior to randomization
- •African-American patients intolerant of or otherwise unable or unwilling to utilize isosorbide dinitrate/hydralazine therapy will be included.
- •Willingness to comply with protocol, attend follow-up appointments, complete all study assessments and provide written informed consent.
排除标准
- •Concurrent or anticipated nitrate use for any reason, or nitrate use within the 14 days prior to screening through the day of randomization.
- •Known allergy, hypersensitivity (anaphylaxis), or adverse reaction to tadalafil or other Phosphodiesterase Type 5 (PDE5) inhibitor
- •Erectile dysfunction treated with a PDE5 inhibitor.
- •Severe renal dysfunction defined as an estimated glomerular filtration rate (GFR) < 30 ml/min/1.73 m^2 or requiring chronic dialysis
- •Current use of alpha antagonists (except carvedilol or tamsulosin) or use of cytochrome P450 3A4 inhibitors (ketoconazole, itraconazole, erythromycin, or cimetidine). Patients who have used a protease inhibitor that is a P450 3A4 inhibitor for longer than one week can be enrolled.
- •Pulmonary arterial hypertension (World Health Organization (WHO) Group I, III-V) for which PDE5 inhibitor therapy may be indicated
- •Severe pulmonary disease requiring home oxygen therapy
- •Comorbidities including clinically significant valvular stenosis (aortic valve area < 0.8 cm^2 or a mitral valve area <1.0 cm^2), uncontrolled hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg) or hypotension (systolic blood pressure <85 mmHg)
- •Chronic intravenous inotrope therapy
- •Non-arteritic anterior ischemic optic neuropathy (NAION)
- •ST elevation MI (STEMI) within 90 days prior to screening
- •Coronary Artery Bypass Grafting (CABG) or mitral valve surgery, initiation of cardiac resynchronization (CRT) or initiation of β-blocker therapy within the 6 months prior to screening
- •Infiltrative or inflammatory myocardial disease (e.g. amyloid, sarcoid)
- •Heart transplant recipient
- •United Network Organ Sharing (UNOS) status 1A or 1B
- •Mechanical circulatory support (MCS) use or planned MCS use at time of consent
- •Active malignancy (except non-melanoma skin cancer) requiring therapy other than observation.
- •Severe non-cardiac illness resulting in life expectancy judged less than three years
- •Known chronic hepatic disease defined as aspartate aminotransferase (AST) and alanine transaminase (ALT) levels > 3.0 times the upper limit of normal
- •Inability to walk even a few steps due to non-cardiac (e.g. orthopedic) reasons
- •Participation in any clinical trial within the last 30 days (with exception of observational study)
- •Previous randomization in PITCH-HF
研究组 & 干预措施
Tadalafil
Active Comparator
Tadalafil is supplied in 20 mg tablets. Subjects will take 20 mg (one tablet) once per day and will be titrated to 40 mg (two tablets once per day) after one week. Subjects are on study drug for the duration of the trial.
干预措施: Tadalafil (Drug)
Placebo
Placebo Comparator
Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
干预措施: Placebo for tadalafil (Drug)
结局指标
主要结局
Composite Outcome of Cardiovascular (CV) Mortality or Heart Failure (HF) Hospitalization
时间窗: Randomization through each subject's last semi-annual visit, up to a maximum of 3 years per subject
次要结局
- Cardiovascular Mortality(Randomization through each subject's last semi-annual visit, up to a maximum of 3 years per subject)
- Heart Failure Hospitalization(Randomization through each subject's last semi-annual visit, up to a maximum of 3 years per subject)
- All-cause Mortality(Randomization through each subject's last semi-annual visit, up to a maximum of 3 years per subject)
- Composite Outcome of All-cause Mortality or CV Hospitalization (Myocardial Infarction, Acute Coronary Syndrome, Stroke, Arrhythmia, or Heart Failure)(Randomization through each subject's last semi-annual visit, up to a maximum of 3 years per subject)
- Frequency of CV Hospitalizations(Randomization through each subject's last semi-annual visit, up to a maximum of 3 years per subject)
- Frequency of HF Hospitalizations(Randomization through each subject's last semi-annual visit, up to a maximum of 3 years per subject)
- Change in 6 Minute Walk Distance From Baseline to 3 Months(Randomization to 3 months)
- Change in MLHFQ Score From Baseline to 3 Months(Randomization to 3 months)
- Change in 6 Minute Walk Distance From Baseline to 18 Months(Randomization to 18 months)
- Trend in 6 Minute Walk Distance From Baseline Through 18 Months(Randomization to 18 months)
- Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score From Baseline to 18 Months(Randomization to 18 months)
- Trend in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score From Baseline Through 18 Months(Randomization to 18 months)
研究者
研究点 (63)
Loading locations...
相似试验
已完成
2 期
Phosphodiesterase-5 Inhibitor in Eisenmenger SyndromeEisenmenger SyndromeNCT01200732Govind Ballabh Pant Hospital28
已完成
3 期
Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and FunctionHeart Defects, CongenitalTransposition of Great Vessels With Ventricular InversionNCT03049540Insel Gruppe AG, University Hospital Bern100
撤回
不适用
Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary HypertensionPrimary and Secondary Pulmonary HypertensionNCT00155714National Taiwan University Hospital20
Unknown
不适用
(Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic HyperplasiaBenign Prostatic HyperplasiaNCT05236634Assiut University120
已完成
3 期
Effect of Tadalafil Once a Day in Men With Erectile DysfunctionErectile DysfunctionNCT00836693Eli Lilly and Company217